Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert I Nicholson

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Cancer Research|February 4, 2015
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancerVerena Thewes, Ronald Simon, Petra Schroeter, et al.
Breast Cancer Research and Treatment|February 25, 2009
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifenHany Onsy Habashy, Desmond G Powe, Cindy M Staka, et al.
European Journal of Cancer (Oxford, England : 1990)|November 24, 2007
Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomesEmad A Rakha, Maysa E El-Sayed, Desmond G Powe, et al.
Cancer Research|December 17, 2008
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survivalJennifer H Law, Golareh Habibi, Kaiji Hu, et al.
Molecular Cancer Therapeutics|July 18, 2013
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancerAndrew Stone, Mark J Cowley, Fatima Valdes-Mora, et al.
The FEBS Journal|July 24, 2013
Global characterization of signalling networks associated with tamoxifen resistance in breast cancerBrigid C Browne, Falko Hochgräfe, Jianmin Wu, et al.
Plos Biology|January 10, 2013
ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancerMaria Kalyuga, David Gallego-Ortega, Heather J Lee, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Cancer Research|February 4, 2015
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancerVerena Thewes, Ronald Simon, Petra Schroeter, et al.
Breast Cancer Research and Treatment|February 25, 2009
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifenHany Onsy Habashy, Desmond G Powe, Cindy M Staka, et al.
European Journal of Cancer (Oxford, England : 1990)|November 24, 2007
Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomesEmad A Rakha, Maysa E El-Sayed, Desmond G Powe, et al.
Cancer Research|December 17, 2008
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survivalJennifer H Law, Golareh Habibi, Kaiji Hu, et al.
Molecular Cancer Therapeutics|July 18, 2013
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancerAndrew Stone, Mark J Cowley, Fatima Valdes-Mora, et al.
The FEBS Journal|July 24, 2013
Global characterization of signalling networks associated with tamoxifen resistance in breast cancerBrigid C Browne, Falko Hochgräfe, Jianmin Wu, et al.
Plos Biology|January 10, 2013
ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancerMaria Kalyuga, David Gallego-Ortega, Heather J Lee, et al.
Pageof 8